Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Impact of test methodology, media type and ion content on the susceptibility of Acinetobacter spp. to tigecycline.

Qu J, Zong Z, Yu R, Hu T, Ye H, Lü X.

J Antimicrob Chemother. 2014 Jun;69(6):1710-1. doi: 10.1093/jac/dkt546. Epub 2014 Jan 30. No abstract available.

PMID:
24481321
2.

Tigecycline disk diffusion breakpoints of Acinetobacter spp.: a clinical point of view.

Curcio D, Fernández F, Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Sader HS.

J Clin Microbiol. 2007 Jun;45(6):2095; author reply 2095-6. No abstract available.

3.

The susceptibility to tigecycline of Acinetobacter spp. may vary depending on the methodology used.

Zárate MS, Serruto G, Smayevsky J.

Int J Infect Dis. 2010 Sep;14 Suppl 3:e351-2. doi: 10.1016/j.ijid.2009.08.015. Epub 2009 Dec 23. No abstract available.

4.

Effect of different Mueller-Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp.

Thamlikitkul V, Tiengrim S.

J Antimicrob Chemother. 2008 Oct;62(4):847-8. doi: 10.1093/jac/dkn267. Epub 2008 Jun 21. No abstract available.

5.

Comment on: Effect of different Mueller-Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp.

Curcio D, Fernández F.

J Antimicrob Chemother. 2008 Nov;62(5):1166-7. doi: 10.1093/jac/dkn328. Epub 2008 Aug 9. No abstract available.

PMID:
18689874
6.

Acinetobacter spp. susceptibility to tigecycline: a worldwide perspective.

Curcio D, Fernández F.

J Antimicrob Chemother. 2007 Aug;60(2):449-50. Epub 2007 Jun 7. No abstract available.

PMID:
17561503
7.

Susceptibility testing of tigecycline against Acinetobacter spp. by disc diffusion method: withdrawing a therapeutic option by varying the Mueller-Hinton agar?

Canigia LF, Bantar C.

J Antimicrob Chemother. 2008 Dec;62(6):1463-4. doi: 10.1093/jac/dkn389. Epub 2008 Sep 8. No abstract available.

PMID:
18782779
8.

In vitro activity of tigecycline against colistin-resistant Acinetobacter spp. isolates from Korea.

Park YK, Choi JY, Song JH, Ko KS.

Int J Antimicrob Agents. 2009 Mar;33(3):289-90. doi: 10.1016/j.ijantimicag.2008.09.005. Epub 2008 Dec 16. No abstract available.

PMID:
19091518
9.

[Variability in the sensitivity to tigecycline against Acinetobacter baumannii in different culture media].

Tenorio-Abreu A, Eiros JM, Rodríguez-Molins E, Andaluz D, Bobillo F, Domínguez-Gil M, Ortiz de Lejarazu R.

Rev Esp Quimioter. 2010 Jun;23(2):76-80. Spanish.

10.

Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp.

Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM, Sader HS.

J Clin Microbiol. 2007 Jan;45(1):227-30. Epub 2006 Nov 8.

11.

Influence of different Mueller-Hinton agars and media age on Etest susceptibility testing of tigecycline.

Tan TY, Ng LS, Chen DM.

Diagn Microbiol Infect Dis. 2010 Sep;68(1):93-5. doi: 10.1016/j.diagmicrobio.2010.05.001.

PMID:
20727479
12.

Comparison of the Etest and broth microdilution method for tigecycline susceptibility testing against clinical isolates of Acinetobacter baumannii from Taiwan.

Liu JW, Jang TN, Cheng YJ, Hsu GJ, Sun W, Lu CT, Hsueh PR; Tigecycline In-Vitro Surveillance in Taiwan (TIST) Group.

Int J Antimicrob Agents. 2010 Feb;35(2):201-2. doi: 10.1016/j.ijantimicag.2009.09.019. Epub 2009 Nov 4. No abstract available.

PMID:
19892530
13.

Comment on: High tigecycline resistance in multidrug-resistant Acinetobacter baumannii.

Thamlikitkul V, Tiengrim S, Tribuddharat C.

J Antimicrob Chemother. 2007 Jul;60(1):177-8; author reply 178-9. Epub 2007 May 11. No abstract available.

PMID:
17496287
14.

Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009).

Mendes RE, Farrell DJ, Sader HS, Jones RN.

Diagn Microbiol Infect Dis. 2010 Nov;68(3):307-11. doi: 10.1016/j.diagmicrobio.2010.07.003.

PMID:
20955916
15.

Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence.

Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME.

J Antimicrob Chemother. 2008 Jul;62(1):45-55. doi: 10.1093/jac/dkn165. Epub 2008 Apr 24. Review.

PMID:
18436554
16.

Tigecycline susceptibility in multidrug resistant Acinetobacter isolates from Turkey.

Yilmaz FF, Taşli H, Gül-Yurtsever S, Büyük A, Hoşgör-Limoncu M.

Pol J Microbiol. 2013;62(3):295-8.

17.

In vitro activity of tigecycline as a therapeutic option against multidrug-resistant Acinetobacter spp.

Eser OK, Ergin A, Tunçkanat F, Hasçelik G.

New Microbiol. 2008 Oct;31(4):535-42.

18.

Are E-test and Vitek2 good choices for tigecycline susceptibility testing when comparing broth microdilution for MDR and XDR Acinetobacter baumannii?

Grandesso S, Sapino B, Amici G, Mazzucato S, Solinas M, Gion M.

New Microbiol. 2014 Oct;37(4):503-8. Epub 2014 Oct 1.

19.

In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan.

Liu JW, Wang LS, Cheng YJ, Hsu GJ, Lu PL, Liu YC, Chen CM, Lee CM, Sun W, Jang TN, Chiang PC, Chuang YC, Lin HC, Shi ZY, Kung HC, Huang CH, Tsao SM, Lu CT, Liao CH, Hsueh PR.

Int J Antimicrob Agents. 2008 Nov;32 Suppl 3:S188-91. doi: 10.1016/S0924-8579(08)70026-8.

PMID:
19013353
20.

Effect of manganese in test media on in vitro susceptibility of Enterobacteriaceae and Acinetobacter baumannii to tigecycline.

Veenemans J, Mouton JW, Kluytmans JA, Donnely R, Verhulst C, van Keulen PH.

J Clin Microbiol. 2012 Sep;50(9):3077-9. doi: 10.1128/JCM.01485-12. Epub 2012 Jun 20.

Supplemental Content

Support Center